ArticleRevista da Sociedade Brasileira de Medicina Tropical2019
Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption.
Article in Revista da Sociedade Brasileira de Medicina Tropical, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pooled it
- Determinants of mortality in carbapenem-resistant Klebsiella pneumoniae ICU Infections: a multivariable clinical and predictive modeling analysis.BMC infectious diseases · 2026Article
- Molecular determinants associated with resistance to imipenem and imipenem-relebactam in clinical Pseudomonas aeruginosa isolates.BMC genomics · 2026Article
- Genomic characteristics and risk factor analysis of carbapenem-non-susceptible Pseudomonas aeruginosa causing bacteremia in a tertiary hospital (2014-2023).BMC microbiology · 2026Article
- Resistance patterns and virulence factors of Pseudomonas aeruginosa in hospitalized patients: A Saudi Arabian study.Scientific reports · 2025Observational
- Antimicrobial susceptibility at intensive care units in Sudan, antibiogram development.BMC microbiology · 2025Article
- Genetic and phenotypic ofIranian journal of microbiology · 2024Article
- Antibiotic susceptibility profile ofIranian journal of microbiology · 2024Article
- Relationship between Antibiotic Consumption and Resistance: A Systematic Review.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Review
- Antibiotic resistance profiles and associated factors of Pseudomonas Infections among patients admitted to large tertiary care hospital from a developing country.Antimicrobial resistance and infection control · 2023Observational
- Virtual Screening of Potential RoxS Inhibitors and Evaluation of Their Antimicrobial Activity in Combination with Antibiotics against Clinically Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2023Article
- The impact of multi-drug resistant Pseudomonas aeruginosa infections on acute pancreatitis patients.BMC infectious diseases · 2023Article
- Evidence-Based Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Evolving trends amongFrontiers in public health · 2023Article
- New Variants of PseudomonasMicroorganisms · 2022Article
- Clinical Efficacy andFrontiers in pharmacology · 2022Article
- Bacteriophage-Based Biosensing ofBiosensors · 2021Article
- Carbapenem-resistant Pseudomonas aeruginosa strains: a worrying health problem in intensive care units.Revista do Instituto de Medicina Tropical de Sao Paulo · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance.
methodsData were obtained from ICUs between 2010 and 2013.
resultsP. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B.
conclusionsMonitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial- and multi-drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.